Phibro Animal Health Corporation (NASDAQ:PAHC – Get Free Report) CEO Jack Bendheim sold 7,040 shares of the company’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $55.91, for a total value of $393,606.40. Following the completion of the transaction, the chief executive officer owned 88,840 shares in the company, valued at $4,967,044.40. This represents a 7.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jack Bendheim also recently made the following trade(s):
- On Thursday, April 30th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.76, for a total value of $371,430.40.
- On Wednesday, April 22nd, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.29, for a total value of $382,201.60.
- On Thursday, April 16th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.64, for a total value of $384,665.60.
- On Tuesday, April 14th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $59.08, for a total value of $415,923.20.
- On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total value of $369,740.80.
- On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total value of $556,300.80.
- On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.66, for a total value of $272,764.80.
- On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total value of $258,244.80.
- On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total value of $378,259.20.
- On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total value of $361,644.80.
Phibro Animal Health Trading Up 1.3%
Shares of NASDAQ PAHC opened at $53.18 on Friday. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 0.81 and a beta of 0.69. The business has a 50 day simple moving average of $53.86 and a 200 day simple moving average of $46.10. Phibro Animal Health Corporation has a 52 week low of $18.33 and a 52 week high of $60.08. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05.
Phibro Animal Health Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th were paid a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health’s payout ratio is presently 21.33%.
Institutional Investors Weigh In On Phibro Animal Health
A number of large investors have recently added to or reduced their stakes in PAHC. 1620 Investment Advisors Inc. boosted its position in Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after purchasing an additional 295 shares during the period. Farther Finance Advisors LLC boosted its position in Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after purchasing an additional 386 shares during the period. Rothschild Investment LLC boosted its position in shares of Phibro Animal Health by 2,500.0% in the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after acquiring an additional 1,000 shares during the period. Hughes Financial Services LLC bought a new stake in shares of Phibro Animal Health in the third quarter valued at approximately $40,000. Finally, iSAM Funds UK Ltd bought a new stake in shares of Phibro Animal Health in the third quarter valued at approximately $61,000. Institutional investors own 99.34% of the company’s stock.
More Phibro Animal Health News
Here are the key news stories impacting Phibro Animal Health this week:
- Positive Sentiment: Phibro amended and expanded its revolving credit facility commitment on April 28, improving liquidity and financial flexibility—an item investors typically view as reducing refinancing risk and supporting growth/capital allocation. Phibro Animal Health Expands Revolving Credit Facility Commitment
- Neutral Sentiment: The company scheduled its third-quarter results release for May 6 and a conference call/webcast for May 7 — a near-term catalyst that could move the stock depending on results vs. expectations. Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results
- Neutral Sentiment: Recent analyst/market commentary has included PAHC in value and GARP stock lists and compared it to peers (e.g., Zacks piece vs. Insulet), which can attract attention from growth-at-a-reasonable-price investors but is not an immediate fundamental change. PAHC vs. PODD: Which Stock Is the Better Value Option?
- Negative Sentiment: CEO Jack Bendheim sold multiple blocks of PAHC shares late April (total reported ~21,120 shares across filings), reducing his ownership; such insider selling can be perceived negatively by the market. Management says the trades were executed under pre-arranged Rule 10b5-1 plans, which moderates the signal but does not eliminate investor concern. SEC Filing Phibro Animal Health’s (PAHC) CEO Sold 21,120 Shares for $1.2 Million
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on PAHC shares. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Morgan Stanley set a $49.00 target price on Phibro Animal Health in a research report on Friday, February 6th. Finally, Citigroup started coverage on Phibro Animal Health in a research report on Wednesday, April 15th. They set a “neutral” rating and a $62.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $42.40.
View Our Latest Analysis on Phibro Animal Health
About Phibro Animal Health
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
Read More
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
